Frankly Speaking LIVE: Women's Health and Other Top Headlines

Sexual function is an important aspect of a full,healthy and happy quality of life. Evidence tells us that female sexual dysfunction (FSD) is common, notably in older women. Estimates of prevelance of FSD are reported to be between 40% to 70% in perimenopausal and menopausal women. Also noted is that a large percentage of clinicians fail to ask about this aspect of health due to many obstacles such as visit time limits and discomfort asking about this sensitive information. Join us as we discuss the recent research about prevalence of FSD, causes of FSD and strategies for obtaining meaningful and sensitive histories, and evidenced based therapies to improve quality of life.

CME/CE Information

1.00 AMA PRA Category 1 Credits™ or 1.00 AANP, including 0.33 AANP Pharm

Release Date: 10/22/2025

Expiration Date: 12/7/2025

Topics

Learning Objectives

Discuss the prevalence and epidemiology of sexual dysfunction in perimenopausal and menopausal women
Discuss strategies for obtaining a pertinent history of sexual function
Discuss evidenced based non-pharmacologic and pharmacologic therapies for sexual dysfunction

Faculty

Frank J. Domino, MD

Professor, Family Medicine and Community Health, University of Massachusetts Chan Medical School, Worcester, Massachusetts

Learn More

Susan Feeney, DNP, FNP, FAANP

Associate Professor, Tan Chingfen Graduate School of Nursing, Associate Dean of Advanced Practice Programs, UMass Chan Medical School, University of Massachusetts Chan Medical School, Worcester, Massachusetts

Learn More

Mariyan L. Montaque, DNP, FNP-BC

Instructor, Department of Family Medicine & Community Health, University of Massachusetts Chan Medical School, Worcester, Massachusetts

Term Lecturer, Family Health Practicum, MGH Institute of Health Professions Inc

Visiting Assistant Professor, Department of Business, Fitchburg State University

Learn More

Disclosures

The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute:

Jill M. Terrien, PhD, ANP-BC: Advisor for GlaxoSmithKline

All others in control of content for this activity have disclosed no relevant financial relationships.

CME/CE Information

AMA PRA Category 1 Credits™

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

Pri-Med Institute is accredited by the American Association of Nurse Practitioners^® as an approved provider of nurse practitioner continuing education. Provider number: 040308.

Designation Statement

This activity is approved for 0.XX contact hour, which includes 0.XX hour of pharmacology.

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.